药物生物等效性。药物生物等效性研究小组给美国国会技术评估办公室的建议。 - Suppr

Suppr

超能文献

Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.

出版信息

J Pharmacokinet Biopharm. 1974 Oct;2(5):433-66.

PMID:4452945

Abstract

摘要

相似文献

Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.药物生物等效性。药物生物等效性研究小组给美国国会技术评估办公室的建议。

J Pharmacokinet Biopharm. 1974 Oct;2(5):433-66.

Bioavailability and bioequivalence.生物利用度与生物等效性。

J Clin Pharmacol. 1976 Oct;16(10 Pt 2):539-45. doi: 10.1177/009127007601601013.

Editorial: Bioavailability, bioequivalence and bias.社论：生物利用度、生物等效性与偏倚

Am J Ophthalmol. 1975 Mar;79(3):518. doi: 10.1016/0002-9394(75)90631-5.

Striving for standards in bioequivalence assessment: a review.生物等效性评估标准的探讨：综述

Int J Clin Pharmacol Ther Toxicol. 1991 Aug;29(8):293-8.

Tests for individual and population bioequivalence based on generalized p-values.基于广义p值的个体和群体生物等效性检验。

Stat Med. 2003 Jan 15;22(1):31-53. doi: 10.1002/sim.1346.

Today's dilemma--will drugs work?当今的困境——药物会起作用吗？

J Am Pharm Assoc. 1971 Jun;11(6):331-3. doi: 10.1016/s0003-0465(16)31670-6.

Assuring total drug quality.确保药品质量全面达标。

J Am Pharm Assoc. 1973 Feb;13(2):96-8.

Antibiotic batch certification and bioequivalence.抗生素批次认证与生物等效性。

JAMA. 1975 Jun 30;232(13):1349-51.

Generic bioequivalence: a scientific consensus needed.普通生物等效性：需要达成科学共识。

Am Fam Physician. 1987 Feb;35(2):91, 95.

Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.

Int J Health Serv. 1974 Winter;4(1):147-55. doi: 10.2190/DCU8-7F68-E48J-4ER5.

引用本文的文献

Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy.口服制剂的生物等效性与生物药剂学分类系统：科学、法规与公共政策。

Clin Pharmacol Ther. 2011 Sep;90(3):467-70. doi: 10.1038/clpt.2011.109. Epub 2011 Jul 20.

A history of biopharmaceutics in the Food and Drug Administration 1968-1993.1968-1993 年美国食品和药物管理局的生物药剂学历史。

AAPS J. 2010 Mar;12(1):44-50. doi: 10.1208/s12248-009-9154-8. Epub 2009 Nov 20.

Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures.左甲状腺素钠生物利用度评估：基于八项设计相同的试验（共396次药物暴露）的汇总分析对改进方法的建议。

Clin Pharmacokinet. 2004;43(14):1037-53. doi: 10.2165/00003088-200443140-00006.

本文引用的文献

Clinically inactive thyroid U.S.P. A preliminary report.美国药典临床无活性甲状腺。初步报告。

N Engl J Med. 1962 Jan 18;266:136-7. doi: 10.1056/NEJM196201182660308.

An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects.不同氯霉素制剂在正常人体受试者中的吸收特性评估。

Clin Pharmacol Ther. 1968 Jul-Aug;9(4):472-83. doi: 10.1002/cpt196894472.

The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters.

J Clin Pharmacol New Drugs. 1971 May-Jun;11(3):187-96.

Variation in biologic availability of digoxin from four preparations.四种制剂中地高辛生物利用度的差异。

N Engl J Med. 1971 Dec 9;285(24):1344-7. doi: 10.1056/NEJM197112092852403.

Assessment of the biologic availability of tetracycline products in man.四环素类产品在人体中的生物利用度评估。

Clin Pharmacol Ther. 1972 Jan-Feb;13(1):97-108. doi: 10.1002/cpt197213197.

Equivalence lack in digoxin plasma levels.地高辛血浆水平缺乏等效性。

JAMA. 1973 Apr 9;224(2):199-204.

Determination of physiologic availability of commercial phenylbutazone preparations.市售保泰松制剂的生理有效性测定。

J Clin Pharmacol New Drugs. 1972 Jul;12(7):296-300. doi: 10.1002/j.1552-4604.1972.tb00061.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验